Systemic Chemotherapy of Melanoma: NMR Studies of Lonidamine & N-Mustard Activity

黑色素瘤的全身化疗:洛尼达明的 NMR 研究

基本信息

  • 批准号:
    8304740
  • 负责人:
  • 金额:
    $ 47.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-05-21 至 2017-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Melanoma remains one of the deadliest of human cancers with no effective method for treating the disseminated disease. We propose to develop an effective method for systemic chemotherapy of melanoma by [tumor] selective [intracellular] acidification to sensitize melanomas to N-mustard alkylating agents. Our strategy is to coadminister glucose with the monocarboxylic acid transport (MCT) inhibitor lonidamine LND in order to trap lactic acid produced by glycolysis in the tumor and to inhibit oxidative metabolism by impeding pyruvate trans- port into mitochondria. This approach depends on the MCT being the key pathway for tumor intracellular pH (pHi) homeostasis, which has been confirmed in our melanoma models. Previous treatment with LND under hyperglycemic conditions led to some mortality. We were funded on this 2yr R01 to develop a safe reproducible method for acidification of human DB1 melanoma xenografts with LND. By administering LND 100 mg/kg i.p. without glucose, we have achieved acidification of the tumor to a pHi of 6.4¿0.1 for at least hr during which time the NTP/Pi ratio of the tumor decreased by 50%; there was no mortality, no significant loss of weight and minimal toxicity associated with this treatment. [LND induced minimal changes in extracellular pH (pHe) of normal tissue, but modified the pH gradient across the plasma membrane of the tumor from pretreatment values of pHi 6.9, pHe 7.0 or !pH=~0 to a post-treatment values of pHi=6.4, pHe=6.85 or !pH=-0.45. Steady state lactate in the tumor increased 3-fold relative to pre-LND levels.] Respiration, EKG, electrolyte levels and blood oxygenation did not change, while blood analysis is still in progress. The pHi and ATP/Pi of skeletal muscle did not change, and there was only a small transient decrease in pHi and ATP/Pi of the liver. Melphalan (LPAM 7.5 mg/kg i.v.)+ LND exhibited a growth delay of 10.5¿0.5 d vs. LND alone, 0.6¿0.7 d. and LPAM alone 1.4¿0.1 d. The [enhanced] response of LPAM to acidification is attributed to an increase in the concentration of the active intermediate (aziridinium ion), a decrease in GSH due to decreased activity of glutathione-S-transferase and a decrease in DNA repair resulting from acid inhibition of O6-alkyl-transferase. Tumor volume decreased by 52.5 ¿12.5%, consistent with the estimated log10 cell kill=0.3012 = log10(2.0). These preliminary studies set the stage for implementation of multidose systemic treatment of xenograft models of human melanoma in preparation for eventual clinical trials. The Aims of this renewal proposal are: 1) To maximize tumor acidification while still avoiding life threatening toxicity by coadministration of low levels of glucose with LND, and to also extend these studies to the more glycolytic DB8 melanoma human xenograft model. 2) Since other N-mustard agents might exhibit similar enhancements of activity at acidic pHi values but perhaps with lower toxicity, LPAM will be compared with cyclophosphamide, chlorambucil and bendamustine under single and multidose administration. 3) To evaluate potential 1H NMR markers for noninvasive early detection of response--lactate and total choline by MRS and apparent diffusion constant (ADC) and T2 measured by MRI. PUBLIC HEALTH RELEVANCE: Melanoma, the most virulent form of skin cancer, is not responsive to chemotherapy. This project proposes to develop a method to sensitize melanomas to chemotherapy by [selective intracellular acidification of] the cancer cells while minimally affecting normal cells. As a basis for future clinic trials, we will identify the optimal drug and optimal conditions for its administration in multiple doses; we will also develop noninvasive NMR methods for early detection of therapeutic response, which will effectively tailor-fit the therapy to the needs of the individual patient.
描述(由申请人提供):黑色素瘤仍然是最致命的人类癌症之一,没有有效的方法来治疗这种播散性疾病。我们建议开发一种有效的黑素瘤全身化疗方法,通过[肿瘤]选择性[细胞内]酸化使黑素瘤对n -芥菜烷化剂敏感。我们的策略是将葡萄糖与单羧酸转运(MCT)抑制剂lonidamine LND共同施用,以捕获肿瘤中糖酵解产生的乳酸,并通过阻碍丙酮酸转运到线粒体来抑制氧化代谢。这种方法依赖于MCT是肿瘤细胞内pH (pHi)稳态的关键途径,这已经在我们的黑色素瘤模型中得到证实。以前在高血糖条件下用LND治疗导致一些死亡。我们在这个为期2年的R01项目中获得资助,开发一种安全可重复的方法来酸化带有LND的人类DB1黑色素瘤异种移植物。通过给予LND 100 mg/kg,不含葡萄糖,我们已经实现了肿瘤的酸化至6.4¿0.1的pHi至少一小时,在此期间,肿瘤的NTP/Pi比率下降了50%;没有死亡,没有显著的体重减轻和最小的毒性与这种治疗相关。[LND诱导正常组织的细胞外pH (pHe)变化很小,但改变了肿瘤质膜上的pH梯度,从预处理值pHi为6.9,pHe为7.0或!pH=~0至处理后值pHi=6.4, pHe=6.85或pH=-0.45。相对于lnd前,稳态乳酸水平在肿瘤中增加了3倍。呼吸、心电图、电解质水平和血氧没有变化,而血液分析仍在进行中。骨骼肌的pHi和ATP/Pi没有变化,肝脏的pHi和ATP/Pi只有短暂的小幅度下降。与单独使用LND相比,Melphalan (LPAM 7.5 mg/kg i.v)+ LND表现出10.5 ~ 0.5 d的生长延迟,0.6 ~ 0.7 d和LPAM单独使用1.4 ~ 0.1 d。LPAM对酸化的[增强]反应归因于活性中间体(aziridinium离子)浓度的增加,谷胱甘肽- s转移酶活性的降低导致GSH的降低,以及o6 -烷基转移酶的酸抑制导致DNA修复的减少。肿瘤体积减少了52.5 ~ 12.5%,与估计的log10细胞杀伤=0.3012 = log10(2.0)一致。这些初步研究为实施人类黑色素瘤异种移植模型的多剂量全身治疗奠定了基础,为最终的临床试验做准备。该更新提案的目的是:1)通过与LND共同施用低水平葡萄糖,最大限度地提高肿瘤酸化程度,同时仍避免危及生命的毒性,并将这些研究扩展到糖酵解性更强的DB8黑色素瘤人类异种移植模型。2)由于其他n -芥菜剂可能在酸性pHi值下表现出类似的活性增强,但可能毒性较低,因此将LPAM与环磷酰胺、氯霉素和苯达莫司汀在单次和多次给药下进行比较。3)评价可能用于无创早期反应检测的1H NMR标记物——MRS测量乳酸和总胆碱,MRI测量表观扩散常数(ADC)和T2。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JERRY D GLICKSON其他文献

JERRY D GLICKSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JERRY D GLICKSON', 18)}}的其他基金

Metabolic Imaging of Targeted Therapies in Cancer
癌症靶向治疗的代谢成像
  • 批准号:
    10551887
  • 财政年份:
    2022
  • 资助金额:
    $ 47.27万
  • 项目类别:
Metabolic Imaging of Targeted Therapies in Cancer
癌症靶向治疗的代谢成像
  • 批准号:
    10391657
  • 财政年份:
    2022
  • 资助金额:
    $ 47.27万
  • 项目类别:
Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition
套细胞淋巴瘤对布鲁顿酪氨酸激酶抑制反应的代谢生物标志物
  • 批准号:
    10362649
  • 财政年份:
    2020
  • 资助金额:
    $ 47.27万
  • 项目类别:
Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase Inhibition
套细胞淋巴瘤对布鲁顿酪氨酸激酶抑制反应的代谢生物标志物
  • 批准号:
    10580590
  • 财政年份:
    2020
  • 资助金额:
    $ 47.27万
  • 项目类别:
Mechanism of Activity of Lonidamine
氯尼达明的活性机制
  • 批准号:
    9071364
  • 财政年份:
    2013
  • 资助金额:
    $ 47.27万
  • 项目类别:
Mechanism of Activity of Lonidamine
氯尼达明的活性机制
  • 批准号:
    8584841
  • 财政年份:
    2013
  • 资助金额:
    $ 47.27万
  • 项目类别:
Mechanism of Activity of Lonidamine
氯尼达明的活性机制
  • 批准号:
    9269066
  • 财政年份:
    2013
  • 资助金额:
    $ 47.27万
  • 项目类别:
Mechanism of Activity of Lonidamine
氯尼达明的活性机制
  • 批准号:
    8882344
  • 财政年份:
    2013
  • 资助金额:
    $ 47.27万
  • 项目类别:
Mechanism of Activity of Lonidamine
氯尼达明的活性机制
  • 批准号:
    8707409
  • 财政年份:
    2013
  • 资助金额:
    $ 47.27万
  • 项目类别:
NMR of Melanoma Acidification, Bioenergetics, Metabolism and Therapeutic Response
黑色素瘤酸化、生物能量学、代谢和治疗反应的 NMR
  • 批准号:
    7740882
  • 财政年份:
    2009
  • 资助金额:
    $ 47.27万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 47.27万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 47.27万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.27万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.27万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.27万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 47.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 47.27万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 47.27万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 47.27万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 47.27万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了